We recently published our article 10 Stocks Under $10 Analysts Believe Could Soar 200%. In this article, we discuss SAB Biotherapeutics Inc. (NASDAQ:SABS) as one of the stocks gaining attention, and here’s a closer look at why it stands out in today’s market.
Stocks trading below $10 have always attracted investors looking for outsized returns. The appeal is easy to understand: a stock rising from $5 to $15 delivers a 200% gain, meaning the investment triples in value. However, a low share price does not automatically mean a company is cheap.
One useful piece of market trivia is that share price and company size are not the same thing. A stock trading at $6 can still represent a multibillion-dollar business if the company has hundreds of millions of shares outstanding. That is why investors searching for the best stocks under $10 should also examine market capitalization, revenue growth, profitability, debt, cash flow, and long-term business prospects.
The companies featured in this article are not small penny stocks. Each has a market capitalization of more than $2 billion and carries a consensus analyst price target suggesting at least 200% upside.
Small-Cap Stocks Are Gaining Momentum
The search for 10 stocks under $10 that could soar 200% comes as smaller companies begin outperforming the broader U.S. stock market.
On July 2, Dominic Pappalardo, Chief Multi-Asset Strategist at Morningstar Wealth, said small-cap stocks could continue delivering above-market returns because their valuations remain attractive compared with large-cap shares.
During 2026, the Morningstar U.S. Small Cap Market Index gained 14%, outperforming the 10.7% increase recorded by the broader Morningstar U.S. Market.
This performance is notable because U.S. small-cap stocks have generally lagged their mid-cap and large-cap peers over the past 15 years. That prolonged underperformance has left many smaller companies trading at discounted valuations, creating potential opportunities for investors looking for undervalued stocks under $10.
The small-cap rally has continued despite a volatile year shaped by geopolitical tensions, including the Iran-U.S. conflict. Latin American stocks have also performed well since the beginning of the war, supported partly by the region’s exposure to oil and other commodities.
Small Caps May Offer Better Diversification
Pappalardo also pointed to diversification as another reason investors may consider small-cap stocks.
Although the S&P 500 includes around 500 companies, approximately 40% of the index is concentrated in its 10 largest holdings. This means a relatively small group of mega-cap companies can have an enormous influence on the performance of the broader market.
Small-cap indexes are generally less concentrated. Their performance is spread across a wider range of industries, including healthcare, financial services, industrials, energy, consumer products, and technology.
This broader exposure could appeal to investors who believe the market has become too dependent on a handful of large technology companies. It may also create opportunities to find high-upside stocks under $10 that are overlooked by investors focused primarily on the biggest names on Wall Street.
Why Stocks Under $10 Can Produce Large Returns
Low-priced stocks can generate dramatic percentage gains because even a relatively small dollar increase can translate into a large return.
For example, a stock rising from $3 to $6 doubles in value. If it reaches $9, it produces a 200% gain. However, the same mathematics also works in reverse. A decline from $6 to $3 results in a 50% loss.
That is why stocks with triple-digit upside potential usually come with considerable risk. A depressed stock price may reflect temporary market pessimism, but it can also signal weak earnings, high debt, slowing demand, regulatory problems, or uncertainty surrounding the company’s business model.
Analyst price targets should therefore be treated as research tools rather than guarantees. A consensus estimate showing 200% upside means analysts see significant recovery potential, but the company may still need to meet ambitious revenue, earnings, or operational expectations.
Small-Cap Valuations Remain Appealing
Morningstar Wealth believes small-cap stocks are more undervalued than they have been in years, while large-cap stocks currently appear expensive.
That valuation gap could support further gains if investors begin shifting money away from highly valued mega-cap stocks and toward smaller companies with stronger recovery potential.
Still, not every inexpensive stock will become a winner. The strongest opportunities may be found in companies with improving fundamentals, manageable debt, competitive advantages, and identifiable growth catalysts.
With that background, let’s examine the 10 stocks under $10 that could soar 200%.
CHECK THIS OUT: Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years andTop 10 Cheap Stocks Under $10 To Buy Now.
Our Methodology
In order to come up with our list of the 10 stocks under $10 that could soar 200%, we screened U.S.-listed stocks trading below $10 with market capitalizations above $2 billion, shortlisted those with at least 200% consensus upside as of the July 10 close, and ranked the 10 qualifying companies in ascending order based on their projected upside.
10 Stocks Under $10 Analysts Believe Could Soar 200%
6. SAB Biotherapeutics Inc. (NASDAQ:SABS)
SAB Biotherapeutics Inc. (NASDAQ: SABS) takes the sixth position among the best stocks under $10 that could triple, with shares recently trading at approximately $3.54 after declining 3.41%. The clinical-stage biotechnology company is developing human polyclonal immunotherapies, with its leading program focused on changing the course of type 1 diabetes.
On July 7, SAB Biotherapeutics Inc. (NASDAQ: SABS) and Breakthrough T1D announced that the diabetes research and advocacy organization had awarded a research grant to Michael J. Haller, M.D., Chief of Pediatric Endocrinology and a professor at the University of Florida.
The funding will support PRISE-hATG, a clinical assessment involving SAB-142 in patients with Stage 3 type 1 diabetes. The study will include individuals who are between approximately 100 days and two years from their initial diagnosis.
The trial is designed to determine whether SAB-142 can preserve endogenous C-peptide and regulate immune responses. C-peptide is commonly used as an indicator of how much insulin a person’s pancreas is still producing. Preserving C-peptide levels could suggest that a therapy is helping protect the remaining insulin-producing beta cells.
This is central to the scientific thesis behind SAB-142. Type 1 diabetes is an autoimmune disease in which the immune system attacks and destroys pancreatic beta cells. By the time many patients are diagnosed, a substantial portion of those cells has already been lost. However, some residual beta-cell function can remain during the period following diagnosis.
The PRISE-hATG assessment will focus on individuals who still have residual beta-cell activity after the first 100 days following a Stage 3 diagnosis. Researchers want to determine whether SAB-142 can help preserve that remaining function while modifying the harmful immune response.
A treatment capable of slowing or altering the progression of type 1 diabetes would represent an important medical advance. Current management generally requires lifelong insulin replacement, blood-glucose monitoring, dietary planning, and constant attention to the risk of high or low blood sugar. Even with modern insulin-delivery systems, the burden on patients and families remains substantial.
On June 24, Barclays analyst Eliana Merle initiated coverage of SAB Biotherapeutics Inc. (NASDAQ: SABS) with an Overweight rating and a $13 price target. Based on the referenced share price, the target represented potential upside of more than 240%.
Merle identified SAB-142 as a potentially valuable disease-modifying treatment for type 1 diabetes. The distinction between disease management and disease modification is crucial. Insulin helps patients control blood-glucose levels, but a disease-modifying immunotherapy could potentially preserve the body’s remaining insulin-producing capacity and address part of the autoimmune process itself.
The analyst expects Phase 2b data for SAB-142 to serve as a major catalyst for SAB Biotherapeutics Inc. (NASDAQ: SABS). Results are anticipated during the second half of 2027, making this a longer-term clinical story rather than a stock built entirely around an immediate catalyst.
The substantial analyst-implied upside reflects the potential value of success in type 1 diabetes. The disease affects a large global patient population and creates lifelong healthcare costs. A treatment that preserves beta-cell function, reduces insulin dependence, improves glucose control, or lowers the risk of complications could attract strong interest from patients, physicians, insurers, and larger pharmaceutical companies.
However, investors must be realistic about the uncertainty involved. Immunotherapies can be difficult to develop because the immune system is highly complex. A treatment must be powerful enough to alter the autoimmune response without producing unacceptable side effects, excessive immune suppression, or other safety problems.
Clinical researchers must also determine the correct patient population, timing, dosage, and treatment duration. A therapy may perform differently in newly diagnosed patients than in those who have lived with type 1 diabetes for several years. The presence or absence of residual beta-cell activity could also affect outcomes.
SAB Biotherapeutics Inc. (NASDAQ: SABS) is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies. Its primary product candidate, SAB-142, is being evaluated in Phase 2b clinical development for autoimmune type 1 diabetes.
The company’s platform is based on producing fully human polyclonal antibodies. Unlike monoclonal antibodies, which generally target a single antigen or pathway, polyclonal antibodies can recognize multiple targets. This broader activity may offer therapeutic advantages in diseases involving complex immune mechanisms, although it can also create additional challenges involving manufacturing, consistency, dosing, and regulatory review.
For SAB Biotherapeutics Inc. (NASDAQ: SABS), the investment case rests on whether this platform can produce a safe and effective treatment capable of changing the progression of type 1 diabetes. The support from Breakthrough T1D adds scientific and advocacy credibility to the program, while the Barclays coverage gives the company greater visibility among institutional investors.
Still, the timeline requires patience. With an important Phase 2b catalyst expected in the second half of 2027, shareholders may face clinical updates, financing events, market volatility, and possible dilution before receiving the most consequential data.
For investors seeking diabetes stocks, immunotherapy stocks, biotechnology stocks under $5, and clinical-stage companies with multibagger potential, SAB Biotherapeutics Inc. (NASDAQ: SABS) stands out because of its ambitious goal. If SAB-142 demonstrates that it can preserve beta-cell function and meaningfully alter the course of type 1 diabetes, the company’s current valuation could change dramatically.
The opposite is also true. A disappointing trial would undermine the central investment thesis and could place severe pressure on the stock. SAB Biotherapeutics Inc. (NASDAQ: SABS) therefore belongs in the high-risk, high-upside category of stocks under $10 that could triple—but only if its science ultimately delivers.
YOU MUST READ THIS: 10 Robotics Stocks to Buy Now as Amazon (AMZN) Hits 1M Robots
Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.
